Statin induced myopathy epidemiology and demographics: Difference between revisions
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{CMG}}; {{AE}} Rim Halaby {{Statin induced myopathy}} ==Overview== The prevalence of statin induced myopathy, described as a spectrum of c...") |
Rim Halaby (talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
The prevalence of [[statin induced myopathy]] | The prevalence of [[statin induced myopathy]] is around 10 to 15%.<ref name="pmid20628837">{{cite journal| author=Harper CR, Jacobson TA| title=Evidence-based management of statin myopathy. | journal=Curr Atheroscler Rep | year= 2010 | volume= 12 | issue= 5 | pages= 322-30 | pmid=20628837 | doi=10.1007/s11883-010-0120-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20628837 }} </ref> | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The prevalence of [[statin induced myopathy]], described as a spectrum of clinical conditions ranging from [[myalgia]] to [[myositis]] and [[rhabdomyolysis]], is | The prevalence of [[statin induced myopathy]], described as a spectrum of clinical conditions ranging from [[myalgia]] to [[myositis]] and [[rhabdomyolysis]], is around 10 to 15%.<ref name="pmid20628837">{{cite journal| author=Harper CR, Jacobson TA| title=Evidence-based management of statin myopathy. | journal=Curr Atheroscler Rep | year= 2010 | volume= 12 | issue= 5 | pages= 322-30 | pmid=20628837 | doi=10.1007/s11883-010-0120-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20628837 }} </ref> | ||
==References== | ==References== | ||
| Line 17: | Line 18: | ||
[[Category:Up-To-Date cardiology]] | [[Category:Up-To-Date cardiology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Best pages]] | |||
Latest revision as of 20:37, 1 December 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby
|
Statin induced myopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Statin induced myopathy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Statin induced myopathy epidemiology and demographics |
|
FDA on Statin induced myopathy epidemiology and demographics |
|
CDC on Statin induced myopathy epidemiology and demographics |
|
Statin induced myopathy epidemiology and demographics in the news |
|
Blogs on Statin induced myopathy epidemiology and demographics |
|
Risk calculators and risk factors for Statin induced myopathy epidemiology and demographics |
Overview
The prevalence of statin induced myopathy is around 10 to 15%.[1]
Epidemiology and Demographics
The prevalence of statin induced myopathy, described as a spectrum of clinical conditions ranging from myalgia to myositis and rhabdomyolysis, is around 10 to 15%.[1]
References
- ↑ 1.0 1.1 Harper CR, Jacobson TA (2010). "Evidence-based management of statin myopathy". Curr Atheroscler Rep. 12 (5): 322–30. doi:10.1007/s11883-010-0120-9. PMID 20628837.